peptidefix

Peptides / SS-31 (elamipretide) / United Kingdom

SS-31 (elamipretide) in the United Kingdom

Legal status, what it is, and the listed suppliers in the United Kingdom that list it.

Legal status in the United Kingdom

Not an approved medicine.

As understood at 2026-09-22. Verify with the MHRA.

What SS-31 (elamipretide) is

SS-31, known as elamipretide in clinical development, is a synthetic four-amino-acid peptide that concentrates in mitochondria and binds cardiolipin, a lipid of the inner mitochondrial membrane. It was developed by Stealth BioTherapeutics. In September 2025 the US FDA granted it accelerated approval, under the brand name Forzinity, for Barth syndrome, a rare genetic mitochondrial disease. That is the only approved use; its other studied uses remain investigational.

Full SS-31 (elamipretide) page: targets and research →

Listed suppliers in the United Kingdom

3 of the 10 suppliers we list in the United Kingdom list SS-31 (elamipretide). Listed, not endorsed: each row is the supplier’s own stated terms.

Imperial Peptides UK United Kingdom In Vitro Research Use Only. Not for human or veterinary consumption. Pure Peptides UK United Kingdom All products are for research use only. XL Peptides United Kingdom All products are exclusively sold for research purposes. They are not intended for human use, therapeutic, diagnostic, or clinical application.

Clinical Research

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
Karaa A, Bertini E, Carelli V, et al. (MMPOWER-3 Trial Investigators) (2023). Neurology. human adults with genetically confirmed primary mitochondrial myopathy, phase 3, n=218
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
Thompson WR, Manuel R, Abbruscato A, et al. (2024). Genetics in Medicine. human people with Barth syndrome, open-label extension, n=10 (8 reached week 168)
Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report
Ortmann L, Velasco D, Cole J (2025). European Heart Journal - Case Reports. human single newborn with Barth syndrome, case report
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
Tung C, Varzideh F, Farroni E, et al. (2025). International Journal of Molecular Sciences. review n/a (review)